[1. Tavassoli FA. Pathology of the Breast, 2nd ed. Stamford, Connecticut; Appleton & Lange; 1999.]Search in Google Scholar
[2. Moinfar F. ed. Essentials of Diagnostic Breast Pathology, Berlin: Heidelberg: Springer; 2007. 10.1007/978-3-540-45120-4]Search in Google Scholar
[3 Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008; 107: 309-330.10.1007/s10549-007-9556-1221762017377838]Search in Google Scholar
[4. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003; 21: 292-300.10.1002/humu.1017412619115]Search in Google Scholar
[5. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13(2): 293-325.10.1677/erc.1.0117216728565]Search in Google Scholar
[6. Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451: 11-18.10.1007/s00428-007-0435-217554555]Search in Google Scholar
[7. De Azambuja E, Cardoso F, De Castro G, Colozzo M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart- Bebhart MJ, Paesmans M. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12.155 patients. Br J Cancer. 2007; 96: 1504-1513.10.1038/sj.bjc.6603756235993617453008]Search in Google Scholar
[8. Eden P, Ritz C, Rose C, Ferno M, Peterson C."Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004; 40: 1837-1841.10.1016/j.ejca.2004.02.02515288284]Search in Google Scholar
[9. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003; 88: 1191-1198.10.1038/sj.bjc.6600886274757612698183]Search in Google Scholar
[10. Pease AC, Solas D, Sullivan EJ, Cronin MT, C. Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA. 1994; 91: 5022-5026.10.1073/pnas.91.11.5022439228197176]Search in Google Scholar
[11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270: 467-470.10.1126/science.270.5235.4677569999]Search in Google Scholar
[12. Perou CM, Sorlie T, Eisen MB, van de Rijin M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikv A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.]Search in Google Scholar
[13. Sorlie T, Perou CM, Tibshiranin R, Aas T, Geisler S, Johnsen H, Hasti T, Eisen MB, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen- Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.10.1073/pnas.1913670985856611553815]Search in Google Scholar
[14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J,. Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 2006; 295(21): 2492-2502.10.1001/jama.295.21.249216757721]Search in Google Scholar
[15. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10): 1684-1691.10.1200/JCO.2009.24.928420194857]Search in Google Scholar
[16. Carey LA. Molecular intrinsic subtypes of breast cancer. In: UpToDate. Hayes DF, Dizon DS, eds. Waltham, MA: UpToDate; 2012. p. 77-84.]Search in Google Scholar
[17. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.10.1038/nature11412346553223000897]Search in Google Scholar
[18. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011; 126(1): 185-192.10.1007/s10549-010-1113-7302607420711652]Search in Google Scholar
[19. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29(29): 3885-3891.10.1200/JCO.2011.36.1105318909021900114]Search in Google Scholar
[20. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010; 116(11): 2549-2559.10.1002/cncr.2501620336785]Search in Google Scholar
[21. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25(43): 5846-5853.10.1038/sj.onc.120987616998499]Search in Google Scholar
[22. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K,. Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109(1):123-139.10.1007/s10549-007-9632-6244310317578664]Search in Google Scholar
[23. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Banchard RA, Lee JC, King TC, Rosenberg CL. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11(2): R18.10.1186/bcr2242268894619320967]Search in Google Scholar
[24. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer. 2011; 117(12): 2747-2753.10.1002/cncr.25862346124321656753]Search in Google Scholar
[25. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26(26): 4282-4288.10.1200/JCO.2008.16.6231636633518779615]Search in Google Scholar
[26. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretoy J, Theocharus C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009; 27(28): 4701-4708.10.1200/JCO.2008.21.707519720911]Search in Google Scholar
[27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9): 1217-1226.10.1016/j.humpath.2006.04.01516938528]Search in Google Scholar
[28. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103(3): 250-263.10.1093/jnci/djq526310757021191117]Search in Google Scholar
[29. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 131(1): 159-167.10.1007/s10549-011-1702-0323794721830014]Search in Google Scholar
[30. Rosai J. Rosai and Ackerman’s Surgical Pathology, 9th ed. London; Mosby; 2004.]Search in Google Scholar
[31. American Joint Committee on Cancer - AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag; 2010.]Search in Google Scholar
[32. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11 (3): 359-377.10.1038/bjc.1957.43207388513499785]Search in Google Scholar
[33. Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A, Sastre-Garau, X. Comparison of the prognostic value of Scarff- Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18(1B): 571-576.]Search in Google Scholar
[34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.10.1111/j.1365-2559.1991.tb00229.x1757079]Search in Google Scholar
[35. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22(3): 207-219.10.1007/BF018408341391987]Search in Google Scholar
[36. Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. Nottingham prognostic index in triple negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011; 11: 299-308.]Search in Google Scholar
[37. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox BS, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt Sj, Scmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12: 207-219.10.1186/bcr2607294963720804570]Search in Google Scholar
[38. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007; 109: 25-32.10.1002/cncr.2238117146782]Search in Google Scholar
[39. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6): 512-6.10.1136/jclinpath-2012-201085]Search in Google Scholar
[40. Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology. 2012; 44(7): 587-95.10.1097/PAT.0b013e328359cf9a]Search in Google Scholar
[41. Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34bE12) is an independent predictor of disease-free survival in patients with triple-negative tumors of the breast. J Clin Pathol. 2010; 63: 744-747.10.1136/jcp.2010.076653]Search in Google Scholar
[42. Gusterson B, Ross D, Heath V, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005; 7: 143-148. 43 Rakha EA, Reis-Filho JS, Ellis IO.Basal-like breast cancer: a critical review. J Clin Oncol. 2007; 26: 2568-2581.]Search in Google Scholar
[44. Cheang M, Voduc D, Bajdik C, Leung S, Mckinney S, Chia SK. Вasal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res. 2008;14: 1368-1376.10.1158/1078-0432.CCR-07-1658]Search in Google Scholar
[45. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7.1 2007: 134.10.1186/1471-2407-7-134]Search in Google Scholar
[46. Salman MI, Elhefnawy NG, Shash LS. Morphological and immunohistochemical characteristics of triple negative and basal breast carcinoma. Egypt J Path. 2012; 32: 6-13.10.1097/01.XEJ.0000417553.95276.37]Search in Google Scholar
[47. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000; 88: 804-813.10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y]Search in Google Scholar
[48. Carter CL, Allen C, Henderson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181-187.10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H]Search in Google Scholar
[49. Korkolis DP, Tsoli E, Fouskakis D, Yiotis G, Koullias J, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are inde pendent prognostic factors in breast cancer patients. Anticancer Res. 2004; 24: 2061-2068.]Search in Google Scholar
[50. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep. 2005; 14: 337-343.]Search in Google Scholar
[51. Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M, Tangoku A. Expression of p53, Ki67, E-cadherin, N-cadherin and Topoisomerase 2A (TOP-2A) in triple negative breast cancer. Anticancer Res. 2011; 31: 2389-2393.]Search in Google Scholar
[52. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hammel N, Goffin JR, Wong N, Trudel M, Kapusta L Porter P, Akslen LA. Advances in brief the prognostic implication of the basal-like phenotype of BRCA1-related breast cancer (cyclin/high/p27low/p53/glomeruloid-microvascularproliferation). Cancer Res. 2004; 64: 830-835.10.1158/0008-5472.CAN-03-2970]Search in Google Scholar
[53. Lerma E, Peiro G, Ramon T, Fernandez S, Martinez D, Pons C, Munoz F, Sabate JM, Alonso C, Ojeda B, Prat J, Barnadas A. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basallike breast carcinomas). Mod Pathol. 2007; 20: 1200-1207.10.1038/modpathol.3800961]Search in Google Scholar
[54. Kreike B, van Kouwenhove M, Horlings H,Weigelt B, Peterse H, Bartelink H, van der Vijver M. Gene expression profiling and histopathological characterization of triple- negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9: R65.10.1186/bcr1771224266017910759]Search in Google Scholar
[55. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int Ј Clin Exp Pathol. 2009; 2: 444-455.]Search in Google Scholar
[56. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing- Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P. Characterization of familial non-BRCA1/2 breast tumours by loss of heterozygosity and immunophenotyping. Clin Cancer Res. 2006; 12: 1693-1700. 10.1158/1078-0432.CCR-05-223016551851]Search in Google Scholar